Impact of pretransplant donor-specific antibodies and human leukocyte antigen mismatches on graft and patient outcomes: A cohort from Saudi Arabia

Table 1 Baseline characteristics, median (interquartile range)

Variable	Category	n (%)
Recipient gender	Male	155 (59.6)
	Female	105 (40.4)
Donor gender	Male	178 (68.5)
	Female	82 (31.5)
Donor type	Living	238 (91.5)
	Deceased	22 (8.5)
DSA presence	Present	151 (58.1)
	Absent	109 (41.9)
Induction therapy	ATG-based	214 (82.3)
	Basiliximab-based	43 (16.5)
	Mixed	3 (1.2)
Plasma exchange	Yes	8 (3.1)
Sensitizing events	None	243 (93.5)
	Re-transplantation	4 (1.5)
	Pregnancy	10 (3.8)
	Blood Transfusion	3 (1.2)
Maintenance therapy	FK + MMF + Pred	256 (98.5)
	CSA + MMF + Pred	4 (1.5)
Re-transplantation	No	255 (98.5)
	Yes	4 (1.5)
IVIG use	No	165 (63.7)
	Yes	94 (36.3)
Acute rejection	Yes	10 (3.8)
	No	250 (96.2)
Graft loss	Yes	12 (4.6)
	No	248 (95.4)
Delayed graft function	Yes	12 (4.6)
	No	248 (95.4)
Mortality	Yes	8 (3.1)
	No	252 (96.9)
CMV infection	Yes	5 (1.9)
	No	255 (98.1)
BKV infection	Yes	5 (2.1)
	No	234 (97.9)
Variable
Recipient age, years	43.0 [31.0-59.2]
Donor age, years	34.0 [28.0-42.0]
ATG dose, mg/kg	4.0 [4.0-5.0]
Length of stay, days	9.0 [8.0-12.0]
Creatinine - 4 months, µmol/L	92.0 [73.5-113.5]
Creatinine - 1 year, µmol/L	89.0 [73.0-111.0]
Creatinine - 2 years, µmol/L	90.5 [71.2-107.8]
eGFR - 4 months, mL/minute/1.73 m2	80.0 [64.0-94.0]
eGFR - 1 year, mL/minute/1.73 m2	83.0 [66.0-98.0]
eGFR - 2 years, mL/minute/1.73 m2	85.0 [71.5-97.0]

DSA: Donor-specific antibody; ATG: Antithymocyte globulin; FK: Tacrolimus; MMF: Mycophenolate mofetil; Pred: Prednisolone; CSA: Cyclosporine; IVIG: Intravenous immunoglobulin; CMV: Cytomegalovirus; BKV: BK virus; eGFR: Estimated glomerular filtration rate.